Chromosomal translocations involving the ERG locus are frequent events in human prostate cancer pathogenesis; however, the biological role of aberrant ERG expression is controversial 1 . Here we show that aberrant expression of ERG is a progression event in prostate tumorigenesis. We find that prostate cancer specimens containing the TMPRSS2-ERG rearrangement are significantly enriched for loss of the tumor suppressor PTEN. In concordance with these findings, transgenic overexpression of ERG in mouse prostate tissue promotes marked acceleration and progression of high-grade prostatic intraepithelial neoplasia (HGPIN) to prostatic adenocarcinoma in a Pten heterozygous background. In vitro overexpression of ERG promotes cell migration, a property necessary for tumorigenesis, without affecting proliferation. ADAMTS1 and CXCR4, two candidate genes strongly associated with cell migration, were upregulated in the presence of ERG overexpression. Thus, ERG has a distinct role in prostate cancer progression and cooperates with PTEN haploinsufficiency to promote progression of HGPIN to invasive adenocarcinoma.
Chromosomal translocations involving the ERG locus are frequent events in human prostate cancer pathogenesis; however, the biological role of aberrant ERG expression is controversial 1 . Here we show that aberrant expression of ERG is a progression event in prostate tumorigenesis. We find that prostate cancer specimens containing the TMPRSS2-ERG rearrangement are significantly enriched for loss of the tumor suppressor PTEN. In concordance with these findings, transgenic overexpression of ERG in mouse prostate tissue promotes marked acceleration and progression of high-grade prostatic intraepithelial neoplasia (HGPIN) to prostatic adenocarcinoma in a Pten heterozygous background. In vitro overexpression of ERG promotes cell migration, a property necessary for tumorigenesis, without affecting proliferation. ADAMTS1 and CXCR4, two candidate genes strongly associated with cell migration, were upregulated in the presence of ERG overexpression. Thus, ERG has a distinct role in prostate cancer progression and cooperates with PTEN haploinsufficiency to promote progression of HGPIN to invasive adenocarcinoma.
The first recurrent translocation event in prostate cancer was recently described 1 . It results in the translocation of an ETS transcription factor gene (ERG or ETV1) to the TMPRSS2 promoter region, which contains androgen responsive elements 1 . The more common TMPRSS2-ERG genetic rearrangement has been reported to occur in approximately 40% of primary prostate tumors and results in an aberrant androgenregulated expression of ERG [1] [2] [3] . Additionally, ETS family members ETV1, ETV4 and ETV5 have been shown to be genetically rearranged to either androgen-regulated or ubiquitous promoter regions, resulting in their aberrant expression in prostate cancer 4, 5 .
Recently, it has been reported that prostate-specific overexpression of ETV1 or ERG results in a very subtle phenotype of hyperplasia and prostatic intraepithelial neoplasia (PIN), a pre-malignant in situ lesion 6, 7 . These data have been interpreted as an indication of a critical proto-oncogenic role for ERG in tumor initiation. Given the subtle phenotypes observed in previously published mouse models, and cellular and molecular studies suggesting that ETS overexpression promotes invasive properties without affecting proliferation, we hypothesized that ERG-associated translocations and the resulting aberrant overexpression of the transcription factor may not in fact represent initiation events but rather critical cooperative progression events in prostate tumorigenesis. Here we present data in support of this hypothesis that, in turn, change our view on the role of aberrant ERG expression in prostate tumorigenesis.
We sought to determine whether ERG genetic rearrangements were present in early prostate cancer lesions. We observed, in fact, that genetic rearrangement of ERG is infrequently found in HGPIN and only in a minority of individuals with prostate cancer lesions, all of whom also have the translocation present in associated adenocarcinoma of the prostate (Fig. 1a) . We evaluated 40 prostate cancer specimens on a tumor tissue microarray for the presence of HGPIN with adjacent carcinoma, of which 10% had evidence of ERG genetic rearrangements as indicated by ERG FISH analysis. All of these cases had the ERG genetic rearrangement in the adjacent invasive prostate cancer as well; however, the majority of prostate cancer specimens with ERG genetic rearrangements do not show this rearrangement in the associated HGPIN, and there were no cases of ERG genetic rearrangements in HGPIN associated with ERG-negative cancers. Similarly, Mosquera et al. 8 reported that ERG genetic rearrangements were found in only 16% of all HGPIN lesions, and in all cases, the adjacent prostate cancer shared the same ERG fusion pattern. Furthermore, of the ERG fusion-positive cancers, 60% did not show ERG genetic rearrangement in the associated HGPIN 8 . In contrast, loss of PTEN has been shown to occur in approximately 45% of HGPIN 9 . Therefore, the TMPRSS2-ERG translocation seems to be an early event in human prostate tumorigenesis, but one potentially associated with progression from HGPIN to cancer.
Primary prostate cancers show genetic loss or alteration (mutation) of at least one PTEN allele in approximately 30-70% of cases 10, 11 . We have previously established a critical role for Pten loss in prostate tumorigenesis [12] [13] [14] . To evaluate whether loss of PTEN and ERG genetic rearrangements are concomitant events in prostate cancer, we analyzed specimens for ERG genetic rearrangements and PTEN protein expression in consecutive sections from a tumor tissue microarray (Fig. 1b) . We analyzed a total of 40 prostate cancer specimens; homogenous PTEN protein expression was reduced or absent in 27 (68%) samples. Homogenous ERG genetic rearrangements as shown by FISH analysis were present in 15 (38%) samples. Notably, 14 of the 15 ERG FISHpositive samples had reduced or absent PTEN expression. Additionally, King et al. found that genomic loss of PTEN and ERG genetic rearrangements are significantly associated (P o 0.002) genetic events 15 . Collectively, these and other published findings 15, 16 highlight that, in human prostate cancer, PTEN loss and ERG genetic rearrangements are concomitant events.
Next, we explored whether aberrant ERG expression was observed in prostate tumors from our mouse models of prostate cancer. We previously showed that conditional knockout of Pten from the prostate results in an indolent form of prostate cancer and that concomitant loss of p53 results in an advanced lethal form of the disease 13, 14 . Surprisingly, we found that expression of mouse Erg is markedly increased at the mRNA level in tumors from prostate conditional Pten À/À ; Trp53 À/À mice compared to prostate tumors from Pten À/À ; Trp53 +/+ mice and control prostates (Fig. 2a) . The upregulation of Erg seems to be selected for during tumor evolution, as Erg transcript levels were similar between primary mouse embryonic fibroblasts (MEFs) of the various genotypes (data not shown).
Given that genetic rearrangements involving ERG are significantly associated with PTEN loss in human prostate cancer, we sought to determine whether aberrant prostatic expression of ERG would cooperate with Pten loss to promote prostate cancer development and progression in mice. Pten heterozygous mice develop HGPIN with an increased proliferative rate after a long latency with incomplete penetrance 12 . To drive ERG expression in the prostate, we generated mice expressing ERG under the control of the probasin (ARR2PB) promoter ( Supplementary Fig. 1 online) . Although the PB-ERG mice did not develop a significant phenotype throughout their lifespan, we found that prostate-specific expression of ERG cooperates with Pten haploinsufficiency, resulting in a highly penetrant phenotype of invasive prostatic adenocarcinoma and a reduction in cancer latency (Fig. 2b) . By 6 months of age, Pten +/À ; PB-ERG mice showed multifocal prostatic adenocarcinoma with complete penetrance (Fig. 2b) . Conversely, control Pten +/À mice do not develop prostatic adenocarcinoma at any age and show HGPIN starting at approximately 8 months of age 12 . Furthermore, Pten +/À ; PB-ERG mice showed a rapid acceleration of disease, with overt HGPIN starting at 2 months of age and progressing to invasive carcinoma by 6 months of age (Fig. 2b) . In the pre-neoplastic prostate glands of PB-ERG mice, ERG overexpression was not associated with a proliferative advantage, whereas Pten +/À mice showed a significant increase in cell proliferation that was not different in the Pten +/À ; PB-ERG compound mice (Fig. 2c) .
We next assessed whether prostate-specific overexpression of ERG would affect Pten levels or function. The levels of Pten and Akt/pAkt were similar between the two genotypes by immunohistochemical staining of histologically normal prostate glands and qRT-PCR analysis ( Fig. 2d and data not shown). Therefore, prostate-specific overexpression of ERG does not seem to directly affect Pten levels; rather, it likely promotes prostate tumorigenesis through a complementary pathway.
To explore the mechanisms by which ERG might promote the development and progression of prostate tumorigenesis, we next studied in vitro ERG-dependent cellular processes. To this end, we generated stable cell lines from BPH-1 cells overexpressing ERG, a constitutively active AKT (AKT-1), or vector control. Protein blot analysis confirmed ERG (Flag) expression, constitutive expression and activation of AKT and phosphorylation status of S6 in these cell lines (Fig. 3a) . In agreement with what was observed in vivo in the prostate of transgenic mice, we found no significant difference in cellular proliferation when ERG was overexpressed (Fig. 3b) . By contrast, overexpression of constitutively active AKT resulted in a proliferative advantage, which was not augmented by ERG overexpression (Fig. 3b) . However, we did observe a marked increase in cell migration when ERG was overexpressed compared to vector control, which was not enhanced by constitutive AKT activation (Fig. 3c) . We subsequently confirmed that ERG overexpression did not alter cell proliferation, but promoted cell migration in both primary MEFs and PC3 cells (data not shown).
To determine the basis underlying the role of ERG in regulating cell migration, we carried out a microarray expression analysis comparing 293 HEK cells overexpressing ERG or vector control. We conducted two independent experiments and looked for genes with a twofold or greater difference across the samples ( Table 1) . We identified a total of 167 differentially expressed genes ( Supplementary  Fig. 2a online) . Two genes, CXCR4 and ADAMTS1, implicated in promoting cell migration and invasion, were found to be transcriptionally upregulated upon ERG expression 17, 18 . CXCR4 is a chemokine receptor implicated in cell migration, cell adhesion, angiogenesis and the homing of hemopoietic cells. Additionally, CXCR4 has been shown to be overexpressed in some carcinomas such as breast, kidney and prostate cancer and transcriptionally regulated by Ets-1 under conditions of hypoxia [19] [20] [21] [22] [23] . These two putative candidates were further validated by quantitative RT-PCR and confirmed to be upregulated in cells overexpressing ERG (Supplementary Fig. 2b ).
To determine whether these genes are direct ERG targets, we searched the 5¢ upstream promoter regions of CXCR4 and ADAMTS1 for putative ETS binding sites. For CXCR4, when analyzing the upstream -3 kb promoter region, we identified two ETS binding sites within 113 bp of each other (Fig. 4a) . For ADAMTS1, the upstream -3 kb promoter region contained a total of four potential ETS binding sites, with two sites within 114 bp of each other (Fig. 4a) . We carried out a chromatin immunoprecipitation (ChIP) assay by overexpressing ERG or vector control in PC3 cells and observed direct binding of ERG to the promoter region for both CXCR4 and ADAMTS1 (Fig. 4a) . We evaluated other regions of the CXCR4 and ADAMTS1 promoters containing potential ERG binding sites; however, none of these areas were different from controls in our ChIP assay. We further demonstrated in replicate ChIP experiments that ERG binds to the promoter region of CXCR4 (Fig. 4b) .
To further evaluate the role of CXCR4 in promoting cell migration in PC3 cells overexpressing ERG, we carried out siRNA knockdown of CXCR4 and control GFP (Supplementary Fig. 2c ). Knockdown of CXCR4 resulted in inhibition of cell migration (Fig. 4c) . Furthermore, we found in vivo that prostate-specific ERG overexpression was associated with transcriptional upregulation of Cxcr4, and to a lesser extent Adamts1 compared to controls (Fig. 4d and Supplementary  Fig. 2d ). Additionally, in Pten loss prostate tumorigenic models selected for Erg upregulation, Cxcr4 transcript levels were also upregulated (Fig. 4e) . Although previous publications have not found a biunivocal correlation of ETS genetic rearrangements and CXCR4 expression levels in human prostate cancer specimens, ETS transcription factors may be only one of the pathways by which CXCR4 levels are regulated 6, 7 . Highlighting this point is the fact that over 80% of primary prostate cancers show upregulation of CXCR4 compared to normal prostate epithelium 24 .
In summary, ERG genetic rearrangements and loss of PTEN are frequent concomitant events in prostate cancer. We have demonstrated that Pten haploinsufficiency cooperates with aberrant ERG expression to accelerate initiation and promote progression of prostatic adenocarcinoma. Pten haploinsufficiency has been shown to promote cell proliferation and the development of prostatic intraepithelial neoplasia, but these lesions do not acquire the properties to progress to invasive disease 12 . However, when Pten haploinsufficiency occurs concomitantly with aberrant ERG expression, the role of ERG on cell migration and invasion rapidly promotes progression of HGPIN to invasive cancer. Given that we also observe acceleration of disease initiation in our Pten +/À ; PB-ERG mouse model, there are likely to be other cellular processes regulated by ERG, yet to be defined, which may cooperate with PTEN loss to promote the initiation of the PIN lesion, such as effects on cell survival, differentiation and DNA repair mechanisms.
Our analyses demonstrate that two frequent critical events in human prostate cancer cooperate to promote tumor development and progression in the prostate. In turn, this knowledge will allow for more accurate patient stratification toward target therapies and prognostication. In fact, Yoshimoto et al. recently showed that the occurrence of these two genetic events in men with prostate cancer has a significant clinical impact 16 . This study showed that the co-occurrence of PTEN loss and ERG genetic rearrangement was a statistically independent predictor of biochemical failure after radical prostatectomy 16 . Moreover, the identification of ERG translocation as a cooperative initiation event in prostate tumorigenesis suggests that ERGtargeted therapies, when feasible, may be effective at preventing the transition between HGPIN and invasive cancer, whereas pharmacological manipulation of the PTEN-PI3K-AKT pathway might represent a powerful chemopreventive and chemotherapeutic tool in the future. Our findings also suggest that targeted therapies against these critical and frequent events should be tested combinatorially in the future, and our current mouse model will provide an effective tool in studying preclinically such combinatorial modalities.
METHODS
Tumor tissue microarray. We generated tumor tissue microarrays for 40 prostate cancer specimens in triplicate and obtained consecutive sections. We carried out FISH on tissue microarrays constructed from cases of prostatic carcinoma with matched HGPIN. We obtained approval from the institutional review board (IRB) and the Human Tissue Utilization Committee (HTUC) before study of human specimens. Break apart FISH probes consisted of two BAC clones each at 5¢ ERG (RP11-55G21 and RP11-110N12) and 3¢ ERG (RP11-315E22 and RP11-720N21), with approximately a 123.35-kb genomic gap between the two sets; and two BAC clones each at 5¢ TMPRSS2 (RP11-35C4 and RP-891L10) and 3¢ TMPRSS2 (RP11-825A8 and RP11-120C17), with an approximately 346.9-kb gap between the two sets. DNA was labeled by nick translation using SpectrumOrange-dUTP (3¢ clones) or SpectrumGreen-dUTP (5¢ clones) (Vysis, Abbott Molecular). Tissue hybridization, washing and fluorescence detection were done as previously described 25 . Samples were analyzed using an automated imaging system with an Axioplan2 fluorescence microscope and scanning stage (Marzhauser) controlled by Metafer 4.0 and Isis 5.0 scanning and imaging software (MetaSystems). PTEN (PTEN Rabbit mAB 9559, Cell Signaling) immunohistochemical staining was done by our molecular cytology core facility.
Generation of plasmid vectors and transgenic construct. We obtained human ERG cDNA sequence (transcript variant 1) from the NCBI database and designed primers (Supplementary Table 1 online) to amplify the entire coding sequence. We used RNA obtained from 293 HEK cells to amplify the human ERG coding sequence, which was subsequently cloned into a TOPO vector (Invitrogen). We carried out sequence analysis to verify appropriate coding sequence and reading frame. This cDNA was then subcloned into a Flag-tag vector (CMV-Tg2B) using restriction enzyme digest with PstI and XhoI. We further subcloned our construct into the MSCV-PIG with the puromycin resistance gene (XhoI) plasmid and the PB-SV40 (XhoI) plasmid using XhoI restriction digest. We obtained MSCV-AKT (constitutively active mutant) with the hygromycin resistance gene from C. Sawyers (Memorial Sloan Kettering Cancer Center). All constructs were screened by sequence analysis to verify appropriate coding sequence and reading frame.
Establishment of PB-ERG mouse colony, genotyping, phenotyping and tissue analysis. To generate a mouse model expressing ERG in a prostatespecific manner, we cloned the human ERG cDNA sequence into a Flag-tag vector, subcloned it into a probasin (ARR2PB)-SV40 expression vector ( Supplementary Fig. 1a ) and established transgenic mice (B6 background) with assistance from our genetically engineered mouse core facility. Mice were subsequently analyzed for construct integration by DNA blot analysis ( Supplementary Fig. 1b) . We identified a total of eight founders positive for the ERG transgene and established F 1 offspring. To ensure similar passage of the transgene to future progeny, we performed DNA blot analysis on our F 1 offspring, revealing similar patterns and intensity for seven of the eight founder lines (Supplementary Fig. 1b) . The founding line with dissimilar transgene passage was killed and excluded from the study. Additionally, we established and validated a PCR genotyping assay for analysis of future progeny. Briefly, we designed primers (Supplementary Table 1 ) to amplify the 3¢ region of probasin and the 5¢ region of ERG and used HOT Star Taq Master Mix Kit (Qiagen) following standard protocols ( Supplementary Fig. 1c ). Our PCR genotyping correlated with our DNA blot analysis in all cases.
We evaluated prostate-specific expression of human ERG at the mRNA and protein levels by quantitative RT-PCR and Flag immunohistochemistry, respectively. Overall, five of the seven original founding lines showed mRNA and three lines showed protein expression of human ERG in all lobes of the prostate, with highest expression in the ventral prostate lobe and dorsal lateral lobe and lowest expression in the anterior lobe ( Supplementary Fig. 1d,e) . We did not observe any detectable transgene levels in the liver, spleen, lung or tail of these mice. There was no difference in mouse Erg expression among our founders and controls ( Supplementary Fig. 1d ). Founding lines labeled A and B were subsequently expanded for phenotypic analysis and crossed into our Pten heterozygous mice to generate F 2 offspring with the genotypes Pten +/+ , Pten +/À , Pten +/+ ; PB-ERG and Pten +/À ; PB-ERG 12 .
All mouse work was done in accordance with our IACUC protocol. Mice were killed using carbon-dioxide asphyxiation, and prostate tissues were procured for formalin fixation, paraffin embedding and frozen storage for future molecular analyses. All tissue processing, paraffin embedding, section and hematoxylin and eosin (H&E) staining was done by Histoserv. Protein from the prostate specimens was extracted by homogenizing the tissue in RIPA buffer. RNA from the prostate specimens was extracted by homogenizing the tissue in TRIzol (Invitrogen). F 2 offspring were generated for two independent transgenic lines (lines A and B) and analyzed for prostate phenotype, with tissue procurement for evaluation as previously described. Results were similar between the two transgenic lines and all data are reported for transgenic line A.
Mouse immunohistochemistry protocols and antibodies. All immunohistochemistry procedures were done through our molecular cytology core facility with previous established protocols for Flag antibody (Santa Cruz), Ki67 antibody (Novocastra), PTEN antibody (Ab-2; NeoMarkers), and phospho serine-473 AKT antibody (Cell Signaling).
Microarray analysis. Microarray analysis was done by our genomics core lab microarray facility. Briefly, MSCV-ERG and vector control were transiently expressed in 293 HEK cells for two independent experiments. RNA was harvested and subsequently quantified and labeled by our core department. Microarray analysis was done on the U133A Affymetrix chip. Results were analyzed using GeneSpring software for twofold differences in gene expression across the two independent experiments and validated with quantitative RT-PCR.
Quantitative RT-PCR protocol and primer sets. Quantitative RT-PCR was done using the SYBR Green PCR light cycler protocol (Qiagen). Subsequently, cDNA was generated from the RNA using the Super Script III First-Strand Synthesis system for RT-PCR (Invitrogen). See Supplementary Table 1 for primer sequences. Analysis was carried out accordingly throughout our experiments, and results were normalized to the house keeping genes ACTB and Hprt for human and mouse specimens, respectively.
Protein blotting protocol and antibodies. Protein lysates were prepared using RIPA buffer and protease inhibitor cocktail (Roche). We used the following antibodies for protein blotting: Flag antibody (Santa Cruz), Actin (AC-74; Sigma), ERG (H-95; Santa Cruz), phospho serine-473 AKT antibody (Cell Signaling) and phospho 240/244 S6 (Cell Signaling).
In vitro analysis of cell phenotype. Cell lines were established from primary MEFs with our MSCV-ERG and MSCV puromycin selection vectors through initial infection and selection with puromycin. Stable clones were established from PC3 and 293 cells with our MSCV-ERG and MSCV puromycin selection vectors through initial transfection and selection with puromycin. BPH-1 cell lines were obtained from S. Hayward (Vanderbilt-Ingram Cancer Center) and infected with MSCV-ERG, MSCV, MSCV-AKT (constitutively active AKT-1), and MSCV-AKT MSCV-ERG and selected with puromycin and hygromycin. These cells were then used for a variety of cellular assays, and all assays were done in triplicate. Protein and RNA were harvested using standard protocols for molecular analyses. For cell proliferation, 1 Â 10 4 cells were plated in 12-well dishes, and cells were trypsinized and counted using a hemocytometer on days 2, 4, 6 and 8. Cell migration assay was done by incubating 1 Â 10 4 cells on a 8.0-mm 24-well plate chamber insert (Falcon) with 0.9% FCS cell media above the insert and cell media containing 10% FCS below the insert to establish a gradient. Cells were incubated for 24 h and subsequently fixed with 4% paraformaldehyde and washed with PBS. Cells adherent to the top of the insert were scraped free with a cotton swab and washed with PBS and cells adherent to the bottom of the insert were stained with crystal violet blue. Positive staining cells were counted across three high-powered fields (Â100).
Chromatin immunoprecipitation (ChIP) protocol. Our protocol was adapted from Strahl-Bolsinger et al. 26 as previously described. Briefly, PC3 cells were transfected with Tg2b-ERG and harvested after 48 h. The cells were fixed using 1% formaldehyde and subsequently washed with PBS. Cells were suspended in ChIP lysis buffer and sonicated at level 2 for 30 s. Immunoprecipitation was carried out with the Flag antibody (Santa Cruz) or control IgG, and beads were washed with 4Â ChIP lysis buffer, 2 ChIP wash buffer, and x Tris buffer, with pelleting of the beads. Immunoprecipitants were eluted in 150 ml of ChIP elution buffer and incubated, and DNA was eluted using the Qiagen PCR purification protocol. We designed primers (Supplementary Table 1 ) to amplify regions of the CXCR4 and ADAMTS1 promoter spanning the putative ETS binding sites.
